Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | DPP4 | P27487 | 13/20 | 0.55 |
| ▸ | ERN1 | O75460 | 5/20 | 0.54 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.49 |
| ▸ | PREP | P48147 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29933323 | 1.00 | KDM4E (0.57) | KDM4EALDH1A1TSHRTDP1DPP4 | |
| SCHEMBL22231506 | 0.93 | ALDH1A1 (0.57) | KDM4EALDH1A1TSHRTDP1DPP4 | |
| SCHEMBL3644816 | 0.85 | ERN1 (0.54) | KDM4EALDH1A1TSHRTDP1DPP4 | |
| SCHEMBL769297 | 0.84 | ALDH1A1 (0.65) | KDM4EALDH1A1TSHRTDP1ERN1 | |
| SCHEMBL1187473 | 0.84 | ALDH1A1 (0.65) | KDM4EALDH1A1TSHRTDP1ERN1 | |
| SCHEMBL29459727 | 0.82 | ALDH1A1 (0.69) | KDM4EALDH1A1TSHRTDP1ERN1 | |
| SCHEMBL9818754 | 0.82 | ALDH1A1 (0.63) | KDM4EALDH1A1TSHRTDP1ERN1 | |
| SCHEMBL7401545 | 0.82 | ALDH1A1 (0.69) | KDM4EALDH1A1TSHRTDP1DPP4 | |
| SCHEMBL1002368 | 0.82 | ALDH1A1 (0.69) | KDM4EALDH1A1TSHRTDP1ERN1 | |
| SCHEMBL11044996 | 0.79 | ALDH1A1 (0.59) | KDM4EALDH1A1TSHRTDP1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112812113-B | Immunomodulatory compounds, compositions and uses thereof | 杭州和正医药有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-112812113-A | Immunomodulatory compounds, compositions and uses thereof | 杭州和正医药有限公司 | 2021-05-18 | — | — | CN | disclosed |
| EP-1899296-B1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7812040-B2 | such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders | PFIZER INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2009-05-21 | — | — | US | disclosed |
| EP-1899296-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006136924-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | HRH3, HRH4, HRH2 | KDM4E 3381/4885ALDH1A1 923/4885TSHR 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.